dc.contributor.author |
Kovalevskaiia, L. |
en |
dc.contributor.author |
Pakhlevanzade, A. |
en |
dc.contributor.author |
Ivanchenko, S. |
en |
dc.contributor.author |
Kupriianova, L. |
en |
dc.contributor.author |
Volianska, V. |
en |
dc.contributor.author |
Plakida, A. |
en |
dc.contributor.author |
Panigrahi, P. |
en |
dc.date.accessioned |
2022-10-25T08:18:55Z |
|
dc.date.available |
2022-10-25T08:18:55Z |
|
dc.date.issued |
2022 |
|
dc.identifier.citation |
Kovalevskaiia L, Pakhlevanzade A, Ivanchenko S, Kupriianova L, Volianska V, Plakida A, Panigrahi P. Cardiovascular Disorders as a Result of COVID-19. Open Access Maced J Med Sci. 2022 Aug 18; 10(B):1862-1868. |
en |
dc.identifier.uri |
https://repo.odmu.edu.ua:443/xmlui/handle/123456789/11579 |
|
dc.description.abstract |
Based on the literature data, we present current literature information about frequency, main spectrum, and prognostic
value of cardiovascular complications of the SARS-CoV-2 infection. We have highlighted in detail the variants of
cardiovascular disorders in the case of patients with SARS-CoV-2 infection caused by concomitant diseases of
hypertension, acute coronary syndrome, myocardial infarction, arrhythmias, virus-associated myocarditis, and
heart failure. We have described the adverse cardiovascular effects of medicines of different groups used to treat
COVID-19 disease and possible medical interactions. We have summarized some current recommendations on
cardiotonic and cardioprotective therapy in the case of patients with cardiovascular complications. |
en |
dc.language.iso |
en |
en |
dc.subject |
COVID-19 |
en |
dc.subject |
Cardiovascular complications |
en |
dc.subject |
Myocardial damage |
en |
dc.title |
Cardiovascular Disorders as a Result of COVID-19 |
en |
dc.type |
Article |
en |